Kartesia, a European provider of capital solutions for small and mid-sized companies, has provided a loan facility to support The Rohatyn Group (TRG) and the Founders of Optimapharm in the refinancing and growth financing of the Company.
The Rohatyn Group is a global asset management firm with expertise in emerging markets and real assets, and strong expertise investing in Eastern Europe and the Healthcare sector. It acquired a majority stake in the Company from its founders in May 2020 and has since supported the Company in its international expansion via acquisitions and organic growth initiatives.
Kartesia has supported the Company and its shareholders with a unitranche loan and a capex & acquisition line, which will be used to refinance the Company and provide additional funds to support Optimapharm with its future growth plans. The capital for this investment comes from Kartesia’s Senior Opportunities I (KSO I) fund and is Kartesia’s first investment in Croatia. Given Optimapharm’s contribution to medical innovation and human health, this transaction also demonstrates Kartesia’s continued focus on companies with a positive societal impact.
